Skip to content
Maui Sky – Lifestyle
Author:
Formation Bio
Formation Bio Announces $600 Million Debut Fund to Expand Drug Development Capacity
October 28, 2026
Anirvan Ghosh Joins Formation Bio as SVP, Head of Translational Sciences
October 8, 2026
Formation Bio Appoints Michael Ehlers as Chief Scientific Officer and Head of R&D
July 22, 2026
Formation Bio Doses First Participant in Phase 1 Trial of BLKR201, a CNS-Penetrant TYK2 Inhibitor
June 9, 2026